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Abstract How lymphocyte counts relate to treatment-
response in patients with ANCA-associated vasculitis
(AAV) is controversial, and data on short-term variability
of lymphocyte counts are lacking. Retrospective single cen-
ter evaluation of disease activity and lymphocyte counts in
patients with AAV, and of lymphocyte counts in kidney
transplant-recipients, were done; both at the University
Hospital Basel, Switzerland. Twenty-three patients with
AAV were included. Remission was achieved in all
patients. Ten patients experienced a relapse after a median
of 66 weeks (range 15–189 weeks). Median lymphocyte
counts at diagnosis were signiWcantly higher than at remis-
sion (1.38 £ 109/L vs. 0.99 £ 109/L; P = 0.007). By con-
trast, median lymphocyte counts at remission and relapse
did not diVer signiWcantly. However, intra-individual vari-
ability of lymphocyte counts early after diagnosis was high
[median lymphocyte variability-range during the Wrst
3 weeks of treatment 1.57 (range 0.27–3.95), n = 17]. This
variability was not speciWc to patients with AAV, but was
also observed in patients after kidney transplantation [vari-
ability of 1.76 (range 0.74–3.95, n = 31)]. The signiWcantly
higher median lymphocyte counts at diagnosis of AAV
make lymphocyte counts a valuable surrogate for the treat-
ment-eYciency in clinical studies. By contrast, on a
patient-level, variability of lymphocyte counts impedes
meaningful interpretation of individual measurements.
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Introduction
Therapeutic options for severe AAV are limited, and ther-
apy—mostly cyclophosphamide (CYC)-based—remains a
balancing act between disease- and treatment-related mor-
bidity and mortality [1, 2]. Factors predicting treatment-
response would hence be important.
Lymphocytes, both of the T- and B-cell lineage, are
thought to be involved in the pathogenesis of AAV [3–6].
How circulating lymphocyte counts relate to disease activ-
ity, however, remains controversial. One study reported
that treatment-induced lymphopenia (·0.5 £ 109/L) is
associated with a high likelihood to achieve sustained
remission [3, 7]. By contrast, another group suggested that,
analogous to patients with systemic lupus erythematodes,
lymphopenia in AAV reXects disease activity, with lym-
phocyte counts actually increasing in patients achieving
remission [8, 9]. While the reason for these contradictory
Wndings remain unclear, neither study has taken into
account short-term variability of lymphocyte counts and
how this might impact study results.
Here, we investigated how in AAV-patients (1) median
lymphocyte counts relate to disease activity on a population
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808 Rheumatol Int (2009) 29:807–810level, and (2) assessed, in these same individuals, short-
term lymphocyte count variability.
Patients and methods
Study populations
After obtaining approval by the institutional review board,
disease activity and lymphocyte counts in patients with
AAV (diagnosed between 1/1992 and 12/2007), and lym-
phocyte counts in kidney transplant-recipients (transplanted
within the living-donor program between 1/2004 and 12/
2006) were retrospectively assessed in patients treated at
the University Hospital Basel, Switzerland. Medical charts
from all patients with a deWnite diagnosis of AAV were
reviewed to obtain demographic, clinical and laboratory data.
Diagnosis and follow-up of AAV
AAV was diagnosed according to American College of
Rheumatology (ACR) criteria [10], the Birmingham Vas-
culits Activity Score (BVAS) [11] was calculated initially
and for every subsequent visit.
Laboratory measurements
Lymphocyte counts were determined via routine Xow-
cytometry (ADVIA® Hematology system, Siemens),
ANCA titers were measured using indirect immunoXuores-
cence (INOVA®, San Diego), and ANCA were speciWed
[myeloperoxydase (MPO) vs. proteinase3 (PR3)], and
quantiWed using enzyme linked immunosorbent systems
(DLD Diagnostika®, Hamburg).
Outcome parameters
Remission of AAV was deWned as complete absence of
clinical symptoms and a daily prednisone-dose ·7.5 mg,
according to published criteria [12]. Relapse was deWned as
de novo disease activity according to the BVAS [11].
Statistical analysis
Discrete variables are expressed as counts (percentage),
continuous variables as medians and ranges. Frequency
comparison was done by Chi-square test. Two-group com-
parison of normally distributed data was performed by
paired or unpaired Student’s t test. For not normally distributed
Table 1 Patients with AAV: 
disease manifestation, treatment 
and response to treatment











m WG 43 K, P, I, M, A, S, E 35 CYC 32 16+
m WG 63 K, A, E 14 CYC 16 2+
m WG 68 K, M 13 CYC 31 343+
m WG 66 K, P, A, S, E 26 CYC 28 438+
m WG 44 K, P, M, A, S, N 23 CYC 25 32
m WG 29 K, P, M 10 CYC 34 223+
m WG 55 K, P, M, A, S, N 13 CYC 58 110+
f WG 70 P, A, S 9 PRED 19 1+
f WG 65 K, M, A, N 22 AZA 17 189
f WG 47 K, P, A, S 14 CYC 24 254+
f WG 77 K, P, M, N 18 CYC 83 15
f WG 33 M 6 MTX 10 93
f WG 22 P, M, A, S 12 CYC 87 38
f WG 71 K, I, M 28 CYC 13 122+
f WG 51 K, M, A 21 CYC 42 167
f WG 27 P, M, S 13 MTX 17 5+
f WG 60 M, A, S, N 15 MTX 38 18
f WG 60 M, A, E 9 MTX 19 168
m CSS 33 P, M, N 17 CYC 26 35
f CSS 67 P, M, A 6 CYC 25 179
f CSS 51 P, S, N 10 CYC 29 294+
m AAV nc 58 K 12 CYC 40 15+
f AAV nc 44 K, P, A 12 AZA 13 66+
Abbreviations: WG Wegener 
granulomatosis, CSS Churg–
Strauss syndrome, AAV nc 
ANCA-associated vasculitis not 
otherwise classiWed. Manifesta-
tion: organ involvement at pre-
sentation, K kidney, P lung, I 
Intestinal, M sinus/mucous, 
A arthritis, S skin, E eye, 
N neurologic, BVAS Birming-
ham Vasculitis Activity Score, 
CYC cyclophosphamide, MTX 
methotrexat, PRED prednisone 
alone, AZA azathioprin, TTR 
time-to-remission in weeks, 
TSR time since remission, + 
indicating ongoing remission123
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Wilcoxon’s matched pair signed rank test for paired data
were used. All testing was two-tailed, and P values <0.05
were considered to indicate statistical signiWcance. For all
statistical analysis STATA 9.2 (Stata Corp®, College Sta-
tion, TX) was used.
Results
Patient’s characteristics
Of the 33 AAV patients identiWed, 23 (70%) were included
in the analysis, 10 patients (30%) had to be excluded from
the analysis because of missing data, being lost during fol-
low-up, or due to concurrent diagnoses other than AAV
necessitating immunosuppressive therapy. Wegener’s gran-
ulomatosis was diagnosed in 18/23 patients (78%), Churg–
Strauss Syndrome in 3/23 patients (13%), two patients had
AAV not otherwise classiWed. A total of 14/23 patients were
female (61%), the median age at diagnosis was 55 years
(range, 22–77 years). Relevant baseline characteristics of
the AAV study population are summarized in Table 1.
Median BVAS at diagnosis was 13 (range 6–35). Sixteen
out of twenty-three patients had CYC as part of their induc-
tion therapy. Median CYC dose-to-remission was 13.5 g
(range, 1.5–76.5 g). All 23 patients (100%) achieved remission
[median time-to-remission, 26 weeks (range 10–87 weeks)],
10/23 patients (43%) experienced a relapse [median time-
to-relapse: 66 weeks (range 15–189)]. The control-cohort
of kidney transplant-recipients (n = 31), transplanted con-
secutively between 2004 and 2006) received immunosup-
pressive regimens containing glucocorticoids, mycophenolate
mofetil, and tacrolimus. Ten/31 (33%) transplant-recipients
were female; the median age at transplantation was
50 years (range, 19–68 years).
Lymphocyte counts
Lymphocyte counts were analyzed (1) cross-sectional (i.e.,
on a population level) at diagnosis and in remission, and (2)
longitudinally (i.e., intra-individually) during the Wrst
3 weeks after diagnosis. On a population level, median
lymphocyte counts at diagnosis [Wrst measurement
1.38 £ 109 L (range: 0.5–3.11)] were signiWcantly higher
than median lymphocyte counts in remission [Wrst measure-
ment in remission, 0.99 £ 109 L (range, 0.17–3.1),
P = 0.007] (Fig. 1). Relapsing and non-relapsing patients
had similar lymphocyte counts both at diagnosis and in
remission [median lymphocyte counts at diagnosis, relaps-
ing patients: 1.54 (range 0.77–3.11), non-relapsing patients:
1.34 (range 0.5–2.56), P = 0.15, median lymphocyte counts
in remission, relapsing patients: 0.94 (range 0.17–3.1), non-
relapsing patients: 0.99 (range 0.41–2.82), P = 0.88]. Time-
to-remission was independent of initial lymphocyte counts
(P = 0.8, Cox regression).
However, serial lymphocyte counts early after diagnosis
[deWned here as ¸4 (range 4–17) measurements during the
Wrst 3 weeks after diagnosis; available in n = 17 AAV-
patients] revealed a high intra-individual variability of
lymphocyte counts, even if measured in very short (daily)
intervals [median intra-individual variability-range; 1.57
Fig. 1 Lymphocyte counts at diagnosis, in remission and at relapse of
AAV. Boxes denote median and interquartile ranges; whiskers denote
ranges
Fig. 2 Variability of serial lym-
phocyte counts during the Wrst 
3 weeks of therapy in patients 
with AAV (left panel) and in pa-
tients after kidney transplanta-
tion (right panel). Boxes denote 
median and interquartile ranges; 
whiskers denote ranges123
810 Rheumatol Int (2009) 29:807–810(range 0.27–3.599)]. The lymphocyte count variability in
patients with AAV was compared to the variability in a
cohort of kidney transplant-recipients during the Wrst
3 weeks after transplantation (n = 31, 4–21 measurements).
The median lymphocyte count at transplantation was
0.95 £ 109/L (range, 0.12–2.8), the median intra-individual
variability-range 1.76 (range 0.74–3.95). Variability of
lymphocyte counts in AAV-patients and transplant-recipi-
ents was similar, excluding an AAV-speciWc phenomenon
(P = 0.48) (Fig. 2).
Discussion
The key observations of this study are that (1) in patients
with AAV median lymphocyte counts on a cohort level are
higher at presentation than in remission, and (2) in a given
AAV-patient intra-individual short-term variability of lym-
phocytes is making their value as an indicator of treatment-
eYciency questionable. The major limitations of our study
are its retrospective design, and the small number of
patients that were studied. Despite these limitations, the
range of the observed short-term lymphocyte count vari-
ability—which is essentially unaVected by the study
design—may have implications possibly extending beyond
the Weld of clinical AAV-research.
In the context of AAV, our data—on a cohort level—are
in-line with the plausible notion stemming from a relatively
large study stating that lymphocyte counts inversely associ-
ate with sustained remission [7]. However, by combining
cohort-derived data and analyses in individual patients, our
results indicate that the value of individual lymphocyte
counts in reXecting treatment-eYciency is limited.
While for now remaining a provocative hypothesis,
short-term (day-by-day!) variability of lymphocyte counts
may also inXuence clinical decision making when judging
immuno-competence, e.g., in patients infected with HIV or
in transplant-recipients.
In summary, our study establishes a surprising short-
term variability of lymphocyte counts both in patients with
AAV, and in a heterogeneous group of kidney transplant-
recipients. Larger, ideally prospective studies integrating
short-term variability of peripheral lymphocyte counts and
disease activity are needed to more deWnitely establish the
value of lymphocyte counts as biomarkers for the treat-
ment-eYciency in patients suVering from AAV.
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